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Intherecentpastthestandardtreatmentofkala-azarinvolvedtheuseofpentavalentantimonialsSb(V).Becauseofprogressiverise
intreatment failureto Sb(V)waslimitedits usein thetreatment programin theIndian subcontinent. Until nowthe mechanismof
actionofSb(V)isnotveryclear.Recent studiesindicatedthatbothparasiteandhostscontributetotheantimonyeﬄuxmechanism.
Interestingly, antimonials show strong immunostimulatory abilities as evident from the upregulation of transplantation antigens
and enhanced T cell stimulating ability of normal antigen presenting cells when treated with Sb(V) in vitro. Recently, it has been
shown that some of the peroxovanadium compounds have Sb(V)-resistance modifying ability in experimental infection with
Sb(V) resistant Leishmania donovani isolates in murine model. Thus, vanadium compounds may be used in combination with
Sb(V) in the treatment of Sb(V) resistance cases of kala-azar.
1.Introduction
Leishmaniasis threatens about350 million men, women, and
children in 88 countries around the world. WHO estimates
the worldwide prevalence to be approximately 12 million
cases, with annual mortality of about 60,000 (http://www
.who.int/vaccine research/diseases/soa parasitic/en/index3
.html#disease%20burden) and around 1-2 million estimated
new cases per year (http://www.who.int/leishmaniasis/en/).
Leishmaniasis is caused by a protozoan parasite of the
genusLeishmania which multipliesin certainvertebratesthat
act as reservoirs of the disease. The parasite is transmitted
to humans through the bite of sandﬂies that have previously
fed on an infected reservoir. The outcome of the disease,
however, depends on the species of Leishmania causing
the infection and the immune response raised against that
infection. The cutaneous form tends to heal spontaneously
leaving the scars, which may evolve into diﬀuse cutaneous
leishmaniasis, recidivans leishmaniasis, or mucocutaneous
leishmaniasis (MCL)dependingonthespeciesofLeishmania
causing infection. Accordingly, patients suﬀer from disas-
trous aesthetic consequences. Whereas cutaneous leishma-
niasis (CL) is the most common form of leishmaniasis,
visceral leishmaniasis (VL) is the most severe one. In fact,
VL can be fatal when left untreated and may cause epidemic
outbreakswith ahighmortalityrate.Avarying proportionof
visceral cases can also evolveintoa cutaneousform known as
post-kala-azar dermal leishmaniasis (PKDL), which requires
lengthyandcostlytreatment. Dependingonthegeographical
areas, a speciﬁc form of Leishmaniasis may be caused by
diﬀerent Leishmania s p p .F o re x a m p l e ,C La n dM C Li n
Central and South America are caused by L. mexicana and
L. braziliensis whereas CL in South and Central Asia and the
MiddleEastiscausedbyL.tropicaandL.major.Similarly,VL
(commonly known “kala-azar”) is caused by L. donovani in
India, Bangladesh, China, Nepal, and Sudan, by L. infantum
in North Africa and southern Europe, and by L. chagasi in
Latin America (http://www.who.int/leishmaniasis/en/). The
majority of MCL cases occur in Bolivia, Brazil, and Peru.
90% of CL cases occur in Afghanistan, Brazil, Iran, Peru,
Saudi Arabia, and Syria. Under immunosuppressive condi-
tions such as acquired immunodeﬁciency syndrome (AIDS),2 Molecular Biology International
dermotropic species of Leishmania parasite has also been
reported to visceralize to give rise VL. Because human
immunodeﬁciency virus (HIV)-1 is a frequent cause of
immunosuppression, an increasing number of cases of HIV-
Leishmania coinfection are being reported in areas where
both infections overlap (geographical distribution of leish-
maniasis. Geneva: WHO.Available at: http://www.who.int/
emc/diseases/leish/leisgeo.html). In addition, HIV modiﬁes
the clinical presentation of all forms of leishmaniasis in the
coinfected patients.
As noted above, some forms of leishmaniasis, for exam-
ple, VL might be fatal for patients if left untreated. In the
absence of an eﬀectivevaccine, the control of leishmaniasis is
solely dependent on chemotherapy. The organoantimonial
compounds have remained as the ﬁrst line of treatment for
all forms of leishmaniasis for more than 60 years. However,
until recently, little is known about the chemical structure
of these compounds and the methods used in the industry
for their preparation [1]. Furthermore, molecular and
cellular mechanisms of their action are not well deﬁned.
In recent years, a large-scale increase in clinical resistance
to pentavalent antimonials has been reported [2, 3]. In
India, 65% of previously untreated patients fail to respond
promptly or relapse after therapy with antimonials [4].
Second-line drugs include pentamidine and ampho-
tericin B, but severe side eﬀects and high cost limit their
use [5]. Miltefosine (hexadecylphosphocholine), originally
developed as an anticancer agent, has now been approved
as the ﬁrst oral drug for leishmaniasis. It can be used for
both antimony-responding and nonresponding patients [6].
Although it shows good eﬃcacy, but it is very expensive
and has a long half-life. Data from phase IV clinical trials in
India involving domiciliary treatment with miltefosine along
with weekly supervision suggest a doubling in the relapse
rate against miltefosine [7]. Beside miltefosine is found to
be a potential teratogen in animals. Since there are very few
aﬀordable drugs in hand, resistance to ﬁrst-line drug(s) has
a very big impact on the treatment of leishmaniasis. This
demands an understanding of the molecular and biochem-
ical mechanisms of clinical resistance, which has become a
World Health Organization priority (http://www.who.int/
tdr/diseases/leish/strategy.htm).
2.Treatmentof Leishmaniasis
and Antimonials
2.1. Historical Perspective of the Disease and Therapy. His-
torically, the cutaneous form of leishmaniasis is a disease of
antiquity and was recognized in the Old World with various
names such as oriental sore, Delhi boil, Baghdad sore, and so
forth. This is an ancientdisease. Descriptions ofconspicuous
lesions have been found on tablets in the library of King
Ashurbanipal from the 7th century BC, some of which are
thought to have been derived from earlier texts dating from
1500 to 2500 BC. In addition, in the 10th century Arab
physicians have described the oriental sore [8, 9]. Similarly,
the visceral form of leishmaniasis in the Old World had
been known with various other names like Jessore fever,
Kala-dukh, Sarkari Beemari, Dumdum fever, Burdwan fever,
Fatal-fever and kala-azar (kala-black; azar- fever). The earli-
est kala-azar epidemic occurred in 1824 in Jessore district of
India(nowinBangladesh),whichhadinitiallybeenconfused
with malaria and named as Jessore fever [10]. This epidemic
killedseveralthousandsofpatientsbecausenotreatment was
known until then. The cutaneous leishmaniasis was used to
be treated by local therapy in the endemic areas. However,
by the end of 19th century in Tashkent, pure lactic acid
was applied to the lesions to cauterize it [11]. Relapses were
treated by removal “scraping” of the lesion with a sharp
spoon. Other cauterizing agents included copper sulfate, old
battery acid, plant extracts and heating of the lesions for 20
hours with water in circulating water baths [11]. The visceral
form of the disease was often diagnosed by enlargement of
abdomen and was anecdotally treated in India by burning
the abdominal skin over the spleen.
Antimony has been used as therapeutics in several
centuries. Some authors have suggested its earliest use in
ancient Egypt for cosmetic purposes. However, it has been
shown that this statement was based on a misreading of
the ancient texts [12] .T h ei m p o r t a n c eo fa n t i m o n yi nt h e
early medicine is well documented, due to the debate created
around their utilization in this period [13]. Paracelsus intro-
duced antimony, as a general panacea in the 16th century
(as published in Leipzig in 1604), and it was acclaimed as
one of the seven wonders of the world. The modern era
of usage of antimony began in 1905 when Plimmer and
Thompson showed the activities of sodium and potassium
tartrate against trypanosomes; subsequently these were used
for the treatment of human trypanosomiasis in Africa. Use
of the trivalent antimonial, tarteremetic was ﬁrst reported
for the treatment of CL by Vianna in 1913 [14], the eﬃcacy
was conﬁrmed against VL by Di Cristina and Caronia in
Sicily [15] and Rogers in India in 1915 [16], but later this
d r u gw a sf o u n dt ob eh i g h l yt o x i ca sw e l la sv e r yu n s t a b l ei n
tropical climate [17]. Shortt from India was not impressed
with the outcome and wrote that antimony tartrate, is an
advance over no treatment at all, rather suboptimal in
terms of clinical resistance and relapses [18]. In another
report Cole [11] also concluded that tartar emetic was “not
much better than no treatment at all.” Tartar emetic was
considered as an irritating drug, since it exhibited side eﬀects
such as cough, chest pain and great depression. This led
to the discovery of pentavalent antimonials. Thereafter, the
pentavalentantimonycompoundureastibaminesynthesized
by Brahmachari, emerged as an eﬀective chemotherapeutic
agent against Indian kala-azar (KA) in 1920 [19, 20]. This
discovery saved millions of lives of poor Indians, for which
Professor Brahmchari was nominated for the Nobel Prize in
1929 (Nobel Prize oﬃcial website) [10]. The development
of the less toxic pentavalent antimonials by Brahmachari,
Schmidt, Kikuth, and others led to the synthesis of anti-
mony gluconate (Solustibosan) in 1937 [21] and sodium
stibogluconate (Pentostam) in 1945 [22]. Now a days the
most commonly used organic compounds of antimony (Sb)
are sodium antimony gluconate (SAG; manufactured by
Albert-David, Kolkata, India) and meglumine antimoniate
(manufactured by Rhone-Poulence, Paris).Molecular Biology International 3
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Figure 1: Proposed structural formula for 364Da and 365Da
ions identiﬁed by ESI (−)-MS in aqueous solutions of meglumine
antimoniate and stibogluconate, respectively. Adapted from [25].
2.2.Structure. StructuresoftwocomplexesofSb(V)with N-
methyl-D-glucamine (meglumine antimoniate or Glucan-
time) or sodium gluconate (sodium stibogluconate or Pen-
tostam) remained unknown for decades due to their amor-
phous state. Recently, NMR and mass spectrometric ap-
proaches have allowed signiﬁcant progress in this arena [1].
Fast-atom bombardment mass spectrometric (FAB-MS)
data of the commercially available meglumine antimoniate
suggests that two molecules of meglumine (NMG) coordi-
nate with a single Sb atom in a symmetrical geometry [23].
On the other hand, positive ion electrospray ionization mass
spectrometric (ESI(+)-MS) analyses indicate the existence of
a mixture of polymeric structures with the general formula
(NMG-Sb)n-NMG [24] .F u r t h e ra n a l y s e so fm e g l u m i n e
antimoniate by ESI-MS, in both the positive and negative
modes, show negatively charged 1:1 (m/z 364) and 2:2
(m/z 765) Sb(V)-meglumine complexes and support the
predominance of zwitterionic species in solution (Figure 1)
[25]. ESI-MS measurements of sodium stibogluconate also
showed that it consists of a mixture of oligomeric structures
[25] that conﬁrmed the earlier results obtained by molecular
sievechromatography[26],andisconsistent withthegeneral
formula for meglumine antimoniate ((GLU-Sb)n-GLU and
(GLU-Sb)n (GLU: gluconate). Osmolarity measurement
suggested the predominance of 1:1 Sb-NMG and Sb-SSG
complexes in diluted samples [25]. This interpretation was
further in agreement with the HPLC-inductively coupled
plasma-MS and ESI-MS analyses [27].
2.3. Entry of Drug. Pentavalent arsenate (As(V)), a metal
r e l a t e dt o( S b ( V ) ) ,i sk n o w nt oe n t e rv i aap h o s p h a t et r a n s -
porter [28]. Antimony transport was ﬁrst studied in both
stages ofLeishmania mexicana and Leishmania donovani par-
asites using (125S b )P e n t o s t a m( S b ( V ) )[ 29]. More recently,
mass spectroscopic approaches reveal the accumulation of
two forms of antimony (Sb(V) and Sb(III)) in both stages
of the parasite. However, accumulation of Sb(V) has been
found to be higher in axenic amastigotes than in promastig-
otes in a number of species [30, 31]. Because gluconate
competitively inhibits uptakeof Sb(V)in axenic amastigotes,
Sb(V) is speculated to enter into the parasites via a protein
that recognizes a sugar moiety-like structure shared with
gluconate [32]. Interestingly, neither As(V) nor phosphate
can compete with the uptake of Pentostam in this scenario.
This ruled out thepossibility that Sb(V) uses an As(V) trans-
porter. However,theaccumulationofSb(III)iscompetitively
inhibited by the related metal As(III) [32], suggesting that
Sb(III) and As(III) enter the cell via the same route.
2.4. Mechanisms of Action. Pentavalent antimonials are in
use against leishmaniases for more than six decades. How-
ever, their molecular and cellular mechanisms of action are
not yet well understood. It is not even clear whether the ﬁnal
active form is Sb(V) or Sb(III). Three main models could be
proposed regarding the mechanism of action of pentavalent
antimonials.
2.4.1. Prodrug Model. According to this model, pentavalent
antimony (Sb(V)) behaves as a prodrug, which undergoes
biological reduction to much more active/toxic trivalent
form of antimony (Sb(III)) that exhibits antileishmanial
activity. However, the site of (amastigote or macrophage)
and mechanism of reduction (enzymatic or nonenzymatic)
remain controversial. Furthermore, the ability of Leishmania
parasites to reduce Sb(V) to Sb(III) is stage-speciﬁc. For
instance, amastigotes but not promastogotes can reduce
Sb(V) to Sb(III). This explains why amastigotes are more
susceptible to Sb(V) but promastigotes are not [33–37].
Other studies have suggested that reduction of Sb(V) to
Sb(III) may also take place within macrophages, but level of
reduction of Sb(V) to Sb(III) in macrophage can not be that
signiﬁcant since Sb(III) even at a dose of ∼25μg/mL can kill
50% of the THP1 macrophages [38, 39]. Thus, conversion of
Sb(V) to Sb(III) may occur at both sites, that is, macrophage
and parasite, and the parasite plays a major role in the
generation of higher, lethal concentrations of Sb(III) within
the parasite. It has been shown that, a proportion of Sb(V)
may be converted to Sb(III) in human [36, 40] and animals
models [41, 42].
The reduction of Sb(V) to Sb(III) requires an active
participation of thiol compounds of both mammalian host
and parasite origin [43–45]. Mammalian thiols, which play
important role in this process, include glutathione (GSH),
cysteine (Cys) and cysteinyl-glycine (Cys-Gly). The ﬁrst one
is the main thiol present in the cytosol, while the second
and the third are the predominant thiols within lysosomes
of mammalian cells [46, 47]. The parasite-speciﬁc thiol
compund, trypanothione (T(SH)2), is a complex consisting
of glutathione and spermidine, has been shown to be
involved in reduction of Sb(V) to Sb(III) [48]. Compared
to GSH, however, the initial rate of reduction of Sb(V) is
m u c hh i g h e ri nt h ep r e s e n c eo fC y s - G l y ,C y s ,a n dT ( S H ) 2
[43]. Generally, acidic pH and slightly elevated temperature
favor reduction of Sb(V) to Sb(III). In vivo this process is
mediated by T(SH)2 within Leishmania parasites and Cys
or Cys-Gly within the acidic compartments of mammalian
cells. But the stoichiometry of GSH and Sb(V) required for
the reduction of antimony is equal to or more than 5:1. As4 Molecular Biology International
the rate of reduction is very low, the physiological relevance
of this conversion is still open to question [49].
Interestingly, promastigotes contain higher intracellular
concentrations of T(SH)2 and GSH than amastigotes [50,
51], and both stages maintain an intracellular pH value
close to neutral [52]. Therefore, nonenzymic reduction of
Sb(V) to Sb(III) fails to account for the insensitivity of
promastigotes to Sb(V). On the other hand, recent studies
have suggested the participation of an parasite-speciﬁc
enzyme, thiol-dependent reductase (TDR1), in the process
of reduction of Sb(V) to Sb(III) [53]. The enzyme TDR1 is
a tetramer protein, containing domains of the omega class
of the glutathione S transferases (GSTs), and using GSH as
the reductant. Although TDR1 has been found to be highly
abundant in the amastigote stage of the parasite, the enzyme
activity and antimony sensitivity in Leishmania amastigotes
could not be directly correlated.
An arsenate reductase homologue in Leishmania parasite
(LmACR2) has also been shown to catalyse the reduction of
Sb(V) in L. major in presence of GSH. LmACR2 requires
glutaredoxin as cofactor for its enzyme activity and is
inhibited by As(III), Sb(III) and phenylarsine oxide [54]. In
contrast to TDR1, LmACR2 is a monomer. Transfection of
LmACR2 in Leishmania infantum promastigotes augments
pentostam sensitivity in intracellular amastigotes, conﬁrm-
ing its physiological signiﬁcance. It is also possible that more
than one mechanism is responsible for the reduction of
Sb(V) to Sb(III).
Mechanism of Killing by Reduced Sb(III). Trypanothione
reductase (TR) and zinc-ﬁnger protein are the potential
molecular targets of Sb(III). Such interaction is consistent
with the modality of Cys binding of thiophilic metals such
as As(III), Sb(III), and Bi(III). Metal-bound Cys systems
are fully deprotonated thiolate anions, the nucleophilicity
of which is greatly attenuated upon formation of metal
complexes with high thermodynamic stability.
Action on Trypanothione/TR System. Trypanothione/TR sys-
temkeepsT(SH)2inthereducedstateand therebymaintains
oxidoreductive balance in Leishmania parasite. This protects
the parasites from oxidative damage and toxic heavy metals,
anddeliversthereducingequivalentsforDNAsynthesis[55].
Although TR shares structural and mechanistic similarity
with glutathione reductase (GR), diﬀerences in the disulﬁde
binding site between TR and GR account for selective
inhibition. Trivalent antimonials interfere with T(SH)2
metabolism by inhibiting TR and inducing rapid eﬄux of
intracellular T(SH)2 and GSH into intact Leishmania cells
[51, 56]. Recently, it has been shown that Sb(III) can bind to
a CCHCzinc-ﬁnger peptide model and promotethe ejection
of Zn(II) [57]. The zinc-ﬁnger domain is characterized by
the coordination of a zinc atom by several amino acid
residues, which are usually cysteines and histidines. These
structural elements are associated with protein-nucleic acid
and protein-protein interactions [58]. The CCHC motif
bearing Zn ﬁnger proteins binds to the hexanucleotide
repeat sequence found in the intervening region of the
GP63 (most abundant surface glycoprotein) gene cluster of
Trypanosomatids. Zn ﬁnger proteins are likelyto be involved
in DNA replication, structure and repair [59]. Treatment
of Leishmania amastigotes with Sb(III) has been found to
induce apoptosis via induction of the oxidative-stress and
increase in intracellular (Ca2+)[ 60, 61].
2.4.2. Intrinsic Antileishmanial Activity Model. According to
this model, Sb(V) has intrinsic antileishmanial activity. In-
itial studies suggested that sodium stibogluconate [Sb(V)]
inhibits macromolecular biosynthesis in amastigotes [62],
possibly via perturbation of energy metabolism due to
inhibition of glycolysis and fatty acid betaoxidation [63].
However, the speciﬁc targets inthese pathwayshave not been
identiﬁed. Sodium stibogluconate, but not Sb(III), specif-
ically inhibits type I DNA topoisomerase, thus inhibiting of
unwinding and cleavage. Sb(III) mediated inhibition seems
to be speciﬁc for Leishmania donovani topoisomerase, since
Sb(III) fails to inhibit calf-thymus topoisomerase I and
Escherichia coli DNA gyrase [64, 65]. Interestingly, in vivo
sensitivity and resistance of Leishmania towards antimonial
drugs have been shown to correlate with the eﬀect of such a
complex [66].
Demicheli and coworkershave reported the formation of
a complexbetweenadenine nucleosidesand Sb(V)[67].For-
mation ofSb(V)-ribonucleosidecomplexes, bothin the ratio
o f1:1a n d1:2w a sevi d e n c e d[ 68, 69]. The large changes for
H2  NMRresonancesuggestedthat–OHgroupsintheribose
are the binding sites for Sb(V) probably via ring chelation at
C2  and C3 . Complex formation between ribonucleosides
andSb(V)was foundtobefaster atacidicpH,indicatingthat
it is kinetically favored in acidic biological compartments.
The rate of dissociation is slow in aqueous solutions at
neutral pH. Moreover, the stability constant determined for
1:1 Sb(V)-GMP complex is consistent with the formation
of such a complex in the vertebrate host following treatment
with pentavalent antimonial drugs, especially if the high
accumulation and prolonged retention of antimony in
macrophages is considered [70, 71]. Regarding the possible
pharmacological role of Sb(V)-ribonucleoside complexes,
two hypotheses may be raised: (a) formation of Sb(V)-
adenine nucleotide complex might act as an inhibitor of
the Leishmania purine transporters, or (b) these complexes
might penetrate inside the parasite, encountering a neutral
pH-environment where dissociation gets retarded and
the complex as such behaves like the purine analog (as
allopurinol), thus interfere with the purine salvage pathway
[72, 73].
2.4.3. Host Immune Activation Model. According to this
model antimonials clear intracellular Leishmania parasites
via activation of host immune system. Action of sodium
antimony gluconate (SAG) is multifaceted. SAG can activate
both innate as well as adaptive immune compartments,
thereby inducingeﬀectiveantileishmanial immune response.
This not only ameliorates existing infection but also protect
from relapse.
Eﬀect onInnate Immunity. Croftand Yardley 2002[74]m en -
tionedamoderateroleforantimonial actionin theparadigmMolecular Biology International 5
“thereticuloendothelialsystem (i.e.,itsstimulation by drugs,
etc.) is of importance for the cure.” Murrayand Nathan [75]
demonstrated that MΦ activation had a signiﬁcant eﬀect on
intracellular parasite killing. Treatment with SAG has been
reported to induce ROS generation in peripheral blood cells
of L. infantum infected mice on stimulation with phorbol
ester (PMA) or zymosan [76], and to induce NO in canine
leishmaniasis [77]. Recently, it has been reported by us [78]
that SAG alone can induce both ROS and NO production in
murine MΦ and promote two wavesof killing of L. donovani
amastigotes.Theﬁrstphaseofkilling(i.e.,atearlytimepoint,
around 6h post treatment) is due to induction of ROS and
the second wave of killing (i.e., at a later time point, 24h and
48h) is mediated by NO generation. Both ROS and NO are
known to be involved in parasite killing in the early stage of
leishmanial infection in mice, whereas NO alone is involved
in the late phase [79, 80]. The role of NO in ﬁnal elimination
ofleishmanial parasites is further strengthened by thestudies
which demonstrated thattreatment ofL.major infected mice
with L-NMMA drastically increases the lesion size and L.
major is visceralized in a late phase of experimental infection
in iNOS knockout mice [81].
SAG Mediating Activation of Signaling Pathways. We further
deciphered the signaling mechanisms responsible for SAG-
induced ROS and NO production and consequent killing of
intracellular leishmania parasites within infected MΦ.S A G -
induced ROS generation in MΦ requires phosphorylation
of ERK via the PI3K-PKC-Ras/Raf pathway. On the other
hand, activation of the PI3K/Akt pathway and downstream
p38MAPK is essential for induction of NO production and
subsequent parasite killing in L. donovani-infected MΦ fol-
lowing SAG treatment. It was further shown that p38MAPK
mediated generation of NO by SAG treatment is an indirect
mechanism. Actually p38MAPK induces TNFα production,
which inturninducesiNOS2expression and subsequentNO
generation since SAG-mediated NO generation and parasite
killing could be abrogated by treatment with antiTNFα
neutralizing antibody [78].
Leishmania infection has been reported to increase
PTPase activity mainly that of SHP1 type [82–84], which
might contribute to dysregulation of PTK dependent sig-
naling events and MΦ deactivation. SAG inhibits SHP1 and
SHP2 classes of PTPases but not MKP1 type [85]b yt h eg l u -
conicacidbackboneboundinvariousspeciﬁc stoichiometric
ratios inhibit puriﬁed SHP1 with speciﬁc eﬃcacies. SHP1
might directly dephosphorylate ERKs [86]m e c h a n i s m sb y
which Leishmania parasites can escape and regulate activa-
tion of other important signaling molecules like PI3K. Thus,
inhibition of SHP1 by SAG might indirectly favor tyrosine
phosphorylation of PI3K and thereby help in activating both
PI3K-PKC-Ras/Raf-ERK1/2 pathway for ROS generation
and the PI3K-Akt-p38 MAPK pathway for NO generation.
In addition, SAG upregulates IFN-γ receptors both in
uninfected and L. donovani infected THP1 cells, as well as in
monocytes derived from kala-azar patients treated with SAG
[87]. Thus it is quite possible that SAG inﬂuences the host’s
antileishmanial defense by altering IFN-gamma responsive-
ness. Indeed, SAG fails to act in IFN-γ knockout mice [88].
We have also observed that SAG and IFN-γ synergize to
produce high levels of NO in MΦs. A combination of SAG
and IFN-γ is also known to be therapeutically much more
eﬀectivethanSAGalone inthe treatment ofvisceral leishma-
niasis [89]. We have further observed that SAG triggers pro-
duction of IL12 in both uninfected as well as infected MΦ.
IL12 is known to induce Th cells to produce IFN-γ,w h i c hi n
turnactivatesMΦstoproduceTNF-alphaand,subsequently,
NO.
2.5. Eﬀect of Antimony on Cell Mediated Immunity
2.5.1. Action on T Cell. Studies of murine VL infections
(BALB/c-L. donovani) have established that an intact T-cell
population, more speciﬁcally Th1, is required for Sb(V) to
produce a curative antileishmanial eﬀect [90, 91]. The drug
itself is leishmanicidal in vitro and in vivo,h o w ev e rc o m p l e t e
cure, in vivo, is not achieved without Th1 input. Patients
coinfected with VL-HIV respond poorly to antimony treat-
ment [92]. After an initial response, these patients frequently
relapse and require alternative treatment [93]. Dermotropic
infections in man usually self-cure. This can take from 3
months to 3 years depending on the species of Leishmania
involved. In such cases antimonial treatment augments the
host’s immune response to rapidly resolve the infection.
Exceptional cases include DCL where, in the absence of a
cell mediated response, antimonials prove to be ineﬀective
[94]. Several studies have shown that endogenous IL-2 [95],
IL-4 [96, 97]a n dI L - 1 2[ 98] inﬂuence the eﬀectiveness of
chemotherapy with pentavalent antimony. These ﬁndings
indicate the requirement of somewhat functional T cell
compartment for SAG action.
Our study indicates that eﬀect of SAGon T cell compart-
ment is corollary to its action on antigen presenting cells like
MΦ. We observed that SAG treatment enhances expression
of speciﬁcally MHC I molecule on the MΦ surface and
enhanced class I mediated antigen presentation, but not the
presentation mediated by MHC class II (Figure 2). This may
be a mechanism by which SAG can enhance antileishmanial
cytotoxic T lymphocyte (CTL) response. There is a report
that CTLs can kill intracellular parasites [99].
Interestingly stimulation of spleen cells, derived from
either Leishmania infected or uninfected mice, induced IFN-
γ generation (Mookerjee Basu, unpublished data). Carter et
al. showed that SAG treatment of infected mice imparted
resistance to reinfection while SAG treatment prior to
infection imparted partial resistance toLeishmania infection.
SAG-induces proliferation of T-cells but not of B cells
(Figure 3)evenin absenceofantigen presentingcells(Mook-
erjee-Basu, unpublished observation). Interestingly SAG-
mediated proliferation of T cells does not require IL-2
(Figure 3).
Thus on the one hand SAG could activate T cell
compartment (in both MHC-independent and -dependent
manner), and on the other could directly activate MΦst o
induce generation of microbicidal eﬀector molecules (ROS
and NO) which in concert help to potentiate both innate and
cellular arms of immune system to eliminate LD parasites.6 Molecular Biology International
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Figure 2: SAG increases MHC classI mediated antigen presentation and upregulates expression of MHC classI. MΦsi s o l a t e df r o mB A L B / c
and C57BL/6 mice, cultured in presence or absence of SAG for 24h. (a) To study the antigen presenting function, peritoneal MΦsf r o m
BALB/c and C57BL/6 mice either kept untreated or treated with SAG for 24h, were used as antigen presenting cells to drive the T-cell
hybridoma in presence of appropriate peptide and IL-2 secretion was tested on IL-2-dependent cell line (HT-2). The growth of HT-2 was
studied using 3H-Thymidine incorporation. The studies showed that class I but not class II restricted presentation was signiﬁcantly (P<
.001) enhanced upon SAG treatment both in normal and infected MΦ. (b) To study the expression of MHC I molecules, untreated (ﬁlled
histogram)andSAG-treated (openhistogram)MΦs fromBALB/cmice were stainedwith FITC labeled anti-Dd (BDPharmingen)according
to manufacturer’s instruction and either analyzed on ﬂow cytometer or examined under a confocal laser scanning microscope. The studies
showedthat classIexpression was signiﬁcantly(P<. 001)enhanced upon SAGtreatment. Antigen presentationassaywas performed atleast
thrice and the results are presented as mean ± SD. For ﬂow cytometry and confocalmicroscopy, representative data of 3 similarexperiments
is presented here.
3.Resistanceto Antimonials
3.1. Clinical Resistance. Pentavalent antimonial drugs were
used worldwide for the treatment of VL and CL for over six
decades with little evidence of resistance. There is a regional
variation in response to antileishmanial drugs and thus rec-
ommendations for treatment of VL vary in diﬀerent regions.
Although the selection of resistant Leishmania has long been
a part of laboratory studies, it is only in the past 15 years that
acquired resistance has become a clinical threat. Pentavalent
antimonials remain the treatment of choice in Africa, South
America, Bangladesh, Nepal, and India (except North Bihar)
at the dose of 20mg/kg/day parenterally for 28–30 days. In
theMediterraneanbasin liposomal amphotericin B(L-AmB)
is the treatment of choice for immunocompetent patients
[100]. The drug of choice for the treatment of HIV/VL coin-
f e c t i o ni sa ne x t e n d e dc o u r s eo fL - A m B[ 101]. However, the
region endemic for VL in North Bihar, India, has the unique
distinction of being the only region in the world where
widespreadprimaryfailuretoSb(V)hasbeenreported[102].
Even in this geographical region a variation in Sb(V) sensi-
tivity occurs with signiﬁcant drug resistance at the epicenter
of the epidemic and a high level of sensitivity only 200 miles
away [103]. This resistance is so far unique to L. donovani;a l l
isolates from a large number of refractory as well as respond-
ing patients in India were identiﬁed as this species [4].
3.2. History of Antimony Resistance. Until the late 1970s, a
small daily dose (10mg/kg; 600mg maximum of Sb(V)) for
short duration (6 to 10 day) was considered adequate. In an
earlier resurgence of Indian VL, which assumed epidemic
proportions by 1977, an estimated 250,000 patients were
aﬀectedinBihar,whenunconﬁrmedreportssuggesteda30%
treatment failure with this regimen from the four districts
most severelyaﬀected,viz Muzaﬀarpur, Samastipur, Vaishali,
and Sitamarhi [104]. Following this, an expert committee
revisedrecommendationstouseSb(V)intwo10-daycourses
with an interval of 10 days and a signiﬁcant improvement in
cure rates (99%) was observed [105]. However, only a few
years later, another study noted 86% cure rates with 20 days
of continuous treatment with this regimen [106]. In 1984, a
WHOexpert committeerecommended that Sb(V)should be
used in doses of 20mg/kg/day up to a maximum of 850mgMolecular Biology International 7
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Figure 3: SAGdirectly stimulatesproliferationofT cells.105 lymphocytes, fromnormalBALB/cmice (a)and5×104 IL-2-dependent CD8+
cytotoxic T cell line (CTLL-2) were plated in each well and were kept either untreated or treated in vitro withvarious concentrations ofSAG.
Proliferation of each type of cells was monitored by 3H thymidine incorporation. Each experiment was performed at least thrice and results
are presented as mean ± SD.
for 20 days, with a repeat of the same regimen for 20 days
in cases of treatment failure. Four years later, Thakur et al.
evaluated the WHO recommendations and reported that 20
days of treatment with 20mg/kg/day (maximum 850mg)
cured only 81% of patients, although with an extension of
the treatment for 40 days 97% of patients could be cured
(Table 1)[ 107].
T h r e ey e a r sl a t e r ,t h es a m eg r o u pn o t e daf u r t h e rd e c l i n e
in cure rate to 71% after 20 days of treatment, and recom-
mended extended duration of treatment in nonresponders.
Mishra et al. [5] found that extending the therapy, to 30 days
could cure only 64% of patients in a hyperendemic district
of Bihar, while 100 percent resistance cases of kala-azar was
observedintwovillagesofDarbhangaandSitamarhidistricts
(182 and 59 cases, resp.). From these ﬁndings it became
clear that Sb(V) refractoriness was increasing although the
reports came from studies that were not strictly controlled.
Intwofollowing studiescarried outunderstrictly supervised
treatment schedules it was observed that only about one-
third of all VL patients could be cured with the currently
prevailing regimen. The incidence of primary unresponsive-
ness was 52%, whereas 8% of patients relapsed. During the
same period, the treatment failed with only 2% of patients
from the neighboring state of (Eastern) Uttar Pradesh [108].
These studies conﬁrmed that a high level of Sb(V) unre-
sponsiveness exists in Bihar, though the drug continues to be
eﬀectivein surrounding areas. There are reports ofantimony
resistance spreading to the Terai regions of Nepal, especially
from the district adjoining hyperendemic areas of Bihar,
whereupto30%ofpatientsseemtobeunresponsive,though
in eastern Nepal a 90% cure rate has been reported [109].
3.3. Reason of Antimony Treatment Failure. The reason for
theemergenceof resistance is widespread misuse ofthedrug.
Sb(V) is freely available in India. Both qualiﬁed medical
practitioners and unqualiﬁed quacks used the drug and this
unrestricted availability of the drug led to rampant misuse.
Most patients (73%) ﬁrst consult unqualiﬁed medical prac-
titioners, who might not use the drug appropriately [110]. It
has been a common practice to start with a small dose and
gradually increase the dose over a week. Drug-free intervals
are given with the belief that they will prevent renal toxicity.
On many occasions the daily dose of drug is split into two
injections, to be given twice daily. These practices presum-
ablyexposetheparasitestodrugpressure,leadingtoprogres-
sive tolerance of the parasite to Sb(V). It has been observed
thatonlyaminorityofpatients(26%)weretreatedaccording
to prescribed guidelines: irregular use and incomplete treat-
ments were a common occurrence. These facts point to the
mishandling ofantileishmanial drugsinBiharasasigniﬁcant
contributor to the development of drug resistance [103].
The growing resistance to Sb(V) in India while it still
remained sensitive all over the world could be due to the
fact that leishmaniasis usually has zoonotic transmission8 Molecular Biology International
Table 1: Changing therapeutic response to pentavalent antimonials(Adapted from T. K. Jha, 2006 [219]).
Study Dose (mg/kg/day) Duration (days) No. of courses No. of cases Unresponsiveness (%)
Jha, (1980) [220] 10 10 1 200 17
Thakur et al., (1984) [221]2 0 2 0 1 6 4 8
>20 1 62 0
Jha, (1986) [222] Child-20 Fresh-30 1 Fresh-73 1.1
Adult-10 Relapse-60 1 Relapse-17
Slow 1
response-42
Thakur et al., (1988) [223] 10 40 1 371 26
15 1 14
20 1 3
Jha, (1992) [224] 20 30 1 252 27.1
Jha, (1995) [225] 20 30 1 32 25
Jha, (1998) [226] 20 30 1 30 37
Thakur et al., (1998) [227] 20 30 1 80 54
Sundar et al., (2001) [102] 20 30 1 184 60
except in the Indian subcontinent and East Africa where the
transmission is largely anthroponotic. In an anthroponotic
cycle,once Sb(V) resistance gets established, it spreads expo-
nentially and organisms sensitive to the drug get eliminated
quickly, whereas the drug-resistant parasites continue to
circulate in the community [111].
In CL the response is not as predictable, because there
is considerable variation in sensitivity to Sb(V) among
primary isolates from untreated patients with cutaneous
leishmaniasis, which correlates with patients’ response to
treatment [112]. Except Bihar, primary resistance is quite
uncommon, but resistance develops in patients with VL,
CL, and MCL who have relapsed. Chances of response to
further courses of antimonials diminish once there is a
relapse afterthe initial Sb(V)treatment [113]. InL. infantum
isolates taken from VL patients in France, drug-sensitive
strains (ED50 < 40μg/mL) were isolated from patients who
responded quickly to meglumine treatment, whereas all
the strains which were resistant under in vitro conditions
(ED50 > 70μg/mL) corresponded to clinical failures. In vitro
sensitivity of strains decreased progressively in relapsing
patients treated with meglumine [2].
3.4. Cellular and Molecular Mechanism of Antimony Resis-
tance. It is evident from the above discussion that the re-
sponse towards antimony treatments dependson several fac-
tors some are parasite related and some are host dependent.
3.4.1. Resistance at the Level of Parasite
Species Variation. Variation in clinical response to the pen-
tavalentantimonials sodium stibogluconate,and meglumine
antimonate (Glucantime) in VL, CL, and MCL has been a
persistent problem in the treatment of leishmaniasis over the
past 50 years. One explanation for this phenomenon is the
intrinsic diﬀerence in species sensitivity to these drugs. In
studiesusing theamastigote-macrophagemodel, L. donovani
and L. brasiliensis were found to be three- to ﬁvefold more
sensitive to sodium stibogluconate than L. major, L. tropica,
and L. mexicana [114]. This was also shown in earlier studies
by Berman et al. using another amastigote macrophage
model, which also demonstrated a wide variation in the
sensitivity of isolates from cutaneous leishmaniasis cases to
pentavalentantimonials [112].Inonecontrolledclinicaltrial
in Guatemala that compared the cure rate to antimonials of
CL caused by diﬀerent species [115], sodium stibogluconate
produced a signiﬁcantly higher cure rate in patients with L.
braziliensis (96%)lesionsthanthose withL. mexicana lesions
(57%).
Role of parasites in antimony treatment failure was
established usingin vitro amastigote-macrophageassay using
L. donovani isolates from responders and nonresponders.
Isolates from patients who did respond to sodium stiboglu-
conate treatment were found be threefold more sensitive,
with 50% eﬀective doses (ED50)a r o u n d2 . 5 μgS b / m L
compared to isolates from patients who did not respond
(ED50 around 7.5μgS b / m L )[ 3]. The signiﬁcant diﬀerences
in amastigote sensitivity supported the concept of acquired
antimony resistance in Bihar.
Other reports on VL isolates from Sudan have also
shown that the clinical response to sodium stibogluconate
was reﬂected in isolates in the amastigote-macrophage
model (but not in promastigotes) [116]. Other observations
support the notion that Sb resistance can be acquired.
Of L. infantum isolates taken from immunodeﬁcient and
immunocompetent VL patients in France both before and
after meglumine antimoniate treatment, those from 13 of
14 patients post-treatment had decreased sensitivity in an
amastigote-macrophage assay [2]. A similar decreased sensi-
tivity was observed in L. infantum isolates taken from dogs
before and after meglumine antimoniate treatment [117].Molecular Biology International 9
In the laboratory, antimonial resistant L. donovani is easily
generatedinculture,mostrecentlyinaxenicamastigotesofL.
donovaniand L.infantum,b u tin vitro unresponsiveness does
not necessarily translate to clinical resistance [118]. Reduc-
tion of drug concentration within the parasite, either by
decreasing drug uptake or by increasing eﬄux/sequestration
of the drug, constitutes the primary mechanism of anti-
monial resistance. Other potential resistance mechanisms
include inhibition of drug reduction, inactivation of active
drug, and gene ampliﬁcation [119–124].
Role of Thiol-Metabolism. Thiol metabolism has a central
role in the maintenance of an intracellular reducing environ-
ment so that the cell can defend itself against the damage
caused by oxidative stress inside the macrophage, oxidants,
certain heavy metals and, possibly, xenobiotics [125]. As
antimony causes oxidative stress [60, 126], a reducing envi-
ronment within the cell and the presence of thiols become
important for antimony resistance. Arsenite- or antimony-
resistant laboratory mutantsofall Leishmania species exhibit
signiﬁcantly increased levels of intracellular thiols, namely
cysteine, GSH, and trypanothione (TSH), suggesting a role
for thiols in resistance [127–129]. The synthesis of two
precursorsGSHand spermidinedeterminesthelevelofTSH.
The γ-GCS gene encoding γ-glutamylcysteine synthetase,
which catalyses the rate-limiting step in GSH biosynthesis,
has been found to be ampliﬁed in arsenite-resistant L. tar-
entolae [130], while the gene ODC which encodes ornithine
decarboxylase, an enzyme involved in the regulation of sper-
midine biosynthesis, is also overexpressed [131, 132]. This
suggests that a lowering of intracellular thiol concentration
may resultin the attenuationof theresistant phenotype.This
proposed hypothesis is conﬁrmed by inhibition studies. The
inhibition of the γ-GCS and ODC genes by their speciﬁc
inhibitors, L-buthionine-(SR)-sulphoximine (BSO) and DL-
a-diﬂuoromethylornithine (DFMO), respectively, results in
the reversal of arsenite or antimony resistance in laboratory
mutants [130, 133]. Although the combination of BSO
and DFMO sensitizes the resistant cells, the residual level
of resistance is still higher than that in wild-type cells,
suggesting that GSH or TSH alone is not suﬃcient to confer
metal resistance. Overexpression of either ODC or γ-GCS in
L. tarentolae wild-type cells results in increased thiol levels,
almost equivalent to those of resistant mutants, but the
transfectants do not exhibit arsenite resistance [130]. While
cotransfection of ODC or γ-GCS with MRPA in wild-type
cells results in arsenite resistance [129, 132], this acquired
resistance in transfectants is also reversed by the thiol deple-
tor BSO [134]. This therefore establishes that MRPA and
increased TSH concentrations act synergistically, and that
TSHavailability is thelimiting factor in both thetransport of
drug conjugates and resistance to arsenite and/or antimony
[135]. The tryparedoxin peroxidase family considered to
be principally responsible for detoxiﬁcation of peroxides
[136]. The decameric type I tryparedoxin peroxidase (TryP)
[137, 138], is a 2-Cys peroxidase, obtaining its reducing
equivalentsfromT(SH)2viathedithiolproteintryparedoxin
(TryX). Studies have associated overexpression of TryP with
resistance to both arsenite [139], and antimony [140]i n
laboratory generated Leishmania resistant lines and in-ﬁeld
isolates [141] implying that enhanced antioxidant defences,
through overexpression of TryP, may well be a key feature of
antimonials resistance. InLeishmania tropicaand Leishmania
mexicana cell lines, an increase in TSH is not associated
with either the ampliﬁcation of γ-GCS or overexpression of
ODC [128]. Interestingly, resistance to Sb(V) in L. donovani
clinical isolates (India) is also reversed in animal models
by treatment with BSO [142, 143]. It is also noteworthy
that the expression of γ-GCS in these resistant isolates is
also increased signiﬁcantly. Interestingly, in another study on
L. donovani isolates from Nepal, expression of γ-GCS and
ODC was signiﬁcantly decreased in resistant isolates [121].
Therefore, there is a need to study the level of thiols in
clinical isolates and determine their role in natural antimony
resistance. It was also shown that antimony-resistant isolates
downregulate the expression of γ-GCS of macrophages
[144], probably by downregulating host NFκB, which is
knowntoregulateγ-GCSexpression [145].Thiswouldresult
inthereductionofintramacrophageGSHlevelsandpromote
an intracellular oxidative environment, thereby minimizing
the intramacrophage reduction of Sb(V) to its toxic form
Sb(III)[39].TheseresultsclearlyindicatethatSAGresistance
in L. donovani is associated with manipulation of both
host and parasite thiol levels. Spontaneous formation of
Sb(III), complexed with GSH or TSH or both, has already
been demonstrated by proton nuclear magnetic resonance
spectroscopy [45, 146]a n db yM S[ 127]. Since GST is
elevatedinmammalian cellsselectedforresistancetoarsenite
[147], it has been proposed that GST mediates the formation
of metalloid thiol pump substrates in Leishmania species
also. However, in Leishmania, GST is not detectable; rather,
a related trypanothione S-transferase activity is observed
[148]. Thus, the thiols have a dual role in antimony resis-
tance, that is, sensitization of the parasite by the reduction of
pentavalent to trivalent antimony, and promotion resistance
by forming conjugates with trivalent antimony for eﬄux
and/or sequestration.
Eﬄux of the Drug. The eﬄux of a drug or its active
derivative isa very commonmechanism ofdrugresistance in
bacteria, yeasts and fungi, and various pathogenic protozoa,
for example, Plasmodium falciparum, Entamoeba histolyt-
ica, Giardia lamblia, Trypanosoma cruzi, and Trichomonas
vaginalis. This may be the case in Leishmania too. Two
types of ABC transporters are known to be responsible for
multidrug resistance (MDR) in cancer cells: P-glycoprotein
(P-gp) and multidrug resistance-related protein (MRP). P-
gp is encoded by the mdr1 gene, which confers resistance
to many hydrophobic drugs (MDR), and is characterized by
reversion with verapamil and cyclosporine A. In Leishmania,
MRP also confers MDR, although this cannot be reversed
by conventional MDR modulators; the protein responsible
is known as MRP1.
InLeishmania, bothclassesofABCtransporters havealso
been reported to be ampliﬁed in various species in response
to diﬀerent drugs under laboratory conditions [149].
Analysis of the complete Leishmania genome (http://
www.genedb.org/) has revealed eight putative protein10 Molecular Biology International
homologues belonging to the MRP1 family, known to be
involved in thiol-associated eﬄux and metal resistance in
mammalian cells [150]. Two of them appear to be involved
in antimony resistance in the parasite. The ﬁrst one is PGPA
(renamed as MRPA). However, Leishmania MRPA is func-
tionally distinct from mammalian MRP, as resistance is not
conferred to pentavalent antimonials, zinc and cadmium, or
the typical multidrug-resistant P-gp substrates vinblastine
and puromycin [151]. The gene has been found to be
ampliﬁed in a number of laboratory mutants of Leishmania
species selected for resistance to Sb(III), Sb(V), and As(III)
[152]. Its role in antimony resistance has been conﬁrmed by
transfection studies [128]. However, this transporter is not
responsible for the drug eﬄux across the plasma membrane.
Rather, it confers resistance by sequestration of metal-thiol
conjugates, a mode of metal detoxiﬁcation in yeast cells [28].
MRPA is localized in membrane vesicles that are close to
the ﬂagellar pocket, the site of endo- and exocytosis in the
parasite[153].OverexpressionofMRPAhasbeenreportedto
decrease inﬂux of antimony rather than increase eﬄux [33],
and this may be due to a dominant negative eﬀect through
interaction with other membrane proteins. Thus, MRPA is
an intracellular rather than an eﬄux transporter, and may
play a major role in antimony resistance [154]. Recently,
it has been shown by DNA microarray assay that MRPA
is overexpressed in the axenic amastigote stage of Sb(III)-
resistant L. infantum [134]. Transfection of MRPA confers
Sb(III) resistance in promastigotes and Sb(V) resistance
in the intracellular stage of L. infantum.H o w e v e r ,M R P A
has not been found to be upregulated in a comparative
transcriptomic study of antimony-resistant L. donovani ﬁeld
isolates [121].
Further, no reports are available regarding the ampliﬁ-
cation of ABC transporter gene(s) in-ﬁeld isolates. Thus, it
is still of great interest to determine whether or not drug-
resistant ﬁeld isolates adopt the same strategies to resist
antimony as the laboratory mutants. A second ABC trans-
porter protein (PRP1), involved in antimony resistance, has
beenisolatedbyfunctional cloningselectingforpentamidine
resistance [155]. This protein has been shown to confer
cross-resistance to antimony. The localization of this protein
and the mechanism by which it confers resistance remain to
be determined. Another transporter that confers antimony
resistance by an active extrusion system independent of
MRPA is also present in L. tarentolae laboratory mutants
[156]. Using everted vesicles enriched in plasma membrane,
it has been shown that a metal eﬄux pump is present in
the Leishmania plasma membrane. Like MRPA, this eﬄux
pump also recognizes the metal conjugated to thiols such as
G S Ha n dT S H[ 127] and requires ATP. The identity of this
eﬄuxpump isstill unknown even10years after itsdiscovery.
Further, it also appears that this eﬄux system does not play
a signiﬁcant role in antimony resistance, as the transport
kinetics of the vesicles prepared from sensitive and resistant
isolates are similar [157].
Dﬀerential gene expression study showed that expression
of aquaglyceroporins AQP1, responsible for Sb(III) uptake,
was downregulated at both the promastigote and the intra-
cellular amastigote stages in antimony-resistant L. donovani
isolates from Nepal [121]. The mRNA of AQP1 has also
been shown to be decreased in antimony-resistant mutants
of several Leishmania species.
3.5. Changes in the Cytoskeleton. Microtubules are dynamic
cytoskeleton polymers consisting of repeating α-/β-tubulin
heterodimers along with α-tubulin, and are vital for cell
shape, growth and diﬀerentiation of Leishmania [158].
Altered expression, polymerisation and cellular distribution
of α-/β-tubulin and apoptosis-like cell death in arsenite
resistant Leishmania donovani promastigotes. Expression of
α-tubulin is similar in both wild-type promastigotes and
arsenite-resistant mutants. A twofold increased sensitivity of
a mutant resistant to Paclitaxel (known to promote tubulin
assembly) is found to decrease the expression of α-tubulin
in arsenite-resistant mutant promastigotes [159]. On the
other hand, the expression level of β-tubulin is higher in
both stages of an arsenite-resistant mutant than in the wild-
type [160], while α-tubulin expression is upregulated in the
amastigote stage only and is unaltered in the promastigote
stage. Although Paclitaxel treatment signiﬁcantly increases
the expression of b-tubulin in resistant promastigotes, it
has no eﬀect on c-tubulin expression in either strain,
either before or after diﬀerentiation [160]. Further, arsenite
treatment has been shown to decrease the expression of
alpha- and betatubulin in wild-type promastigotes, while
expression remains unaltered in an arsenite-resistant mutant
[161]. Since tubulin synthesis is regulated by the unpoly-
merized tubulins, and arsenite has been shown to inhibit
microtubule polymerization in the parasite, arsenite may
decrease the synthesis of tubulins by inhibiting polymer-
ization. It is noteworthy that phosphorylation of α- and β-
tubulin is highly increased in the arsenite-resistant mutant
[162]. Phosphorylation of tubulins could directly aﬀect the
dynamics of tubulin assembly and regulate and aﬀect several
signal-transductionpathways[163].SinceAsandSbareboth
are metalloid and mutual cross resistance has been seen
in some Leishmania mutants, it could be speculated that
tubulin may play an important role in Sb resistance.
3.6. Resistance at the Level of Host. The immune status of
Leishmania infected patients has long been known to aﬀect
drug eﬃcacy. This has proven to be of particular importance
inrelationtopentavalentantimonialtreatment ofDCL[164]
and coinfections with HIV in the visceral form [165, 166],
where there is both an absence of a speciﬁc T-cell mediated
immune response and mutual exacerbation of infection. The
basis for this lack of activity of pentavalent antimonials
has been explored in immunodeﬁcient mouse models for
which the eﬀects are probably due to deﬁciencies of both
Th1-cell-mediated and macrophage responses [90, 167]. The
introduction of highly active antiretroviral therapy [168]
again suggesting an important role for CD4 lymphocytes in
preventing relapses and controlling the infection.
It was further shown by our group that antimonials
activate important signaling pathways of host immune cells
like macrophage to induce ROS and NO that ultimately
leads killing of intracellular parasites [78]. Interestingly, SAGMolecular Biology International 11
can also induce the generation of gamma interferon from
splenic lymphocytes and the proliferation of splenocytes
[169]. Therefore, it was necessary to decipher the role
played by the host cell, if any, in Sb unresponsiveness.
Further endeavor in this direction by our group revealed
that resistant parasites strongly increase expression of host’s
P-gp and MRP1 transporters on the surface of infected
macrophages resulting in Sb clearance from the host cells in
thec ours eofin vitro as well as in vivoexperimental infection.
Moreover, studies performed on patient samples from Sb-
resistant infection areas unequivocally indicate that a similar
phenomenon occurs during natural human infection. In
contrast to infection with Sb-sensitive L. donovani isolates,
infection with Sb-resistant L. donovani isolates upregulates
the multidrug resistance-associated protein 1 (MRP1) and
the permeability glycoprotein (P-gp) in host cells, thus
inhibiting intracellular drug accumulation [170]. Indeed, it
is well established that monocytes do not harbor parasites
at the active stage of the disease. In spite of this, peripheral
blood monocytes from Sb(V) resistant VL patients upreg-
ulate P-gp and MRP1. Therefore, it is likely that soluble
and circulating parasite antigens can cause upregulation
of expression of these transporters. This is supported by
our ﬁndings that formalin-ﬁxed Sb resistant L. donovani
or even extracts from Sb resistant L. donovani strains can
induceupregulationofMRP1andP-gpinuninfectedmurine
macrophages and reduce Sb accumulation following SAG
treatment. Thus the resistance mechanism may operate in
diﬀerent cells of parasite reservoirs even in the absence
of parasite replication in situ. Our results also show that
inhibitors ofP-gp and MRP1 couldrestore sensitivity toward
Sb not only in vitro but also in vivo.I na n i m a lm o d e l s ,
inhibition of the proteins MRP1 and P-gp by lovastatin
reverses their action on drug accumulation and allows
them to escape a fatal outcome. These results indicate that
lovastatin, which can inhibit P-gp and MRP1, might be
beneﬁcial for reverting Sb resistance in VL.
A recent study [171]b yo u rg r o u ph a ss h o w nt h a t
antimony sensitive and resistant clinical isolates of L.
donovani diﬀerentially regulate activation of dendritic cells
(DCs). SAG-induced signaling pathway associated with DC
activation/maturation is selectively targeted by antimony
resistant L. donovani infection. In contrast to antimony sen-
sitive L. donovani, antimony resistant L. donovani infection
inhibits SAG-induced proinﬂammatory cytokine secretion
as well as upregulation of costimulatory molecule and
MHC expression in DCs. Antimony resistant L. donovani
mediates these inhibitory eﬀects in DCs by blocking SAG-
inducedactivation ofthe PI3K/AKTand downstream NF-κB
pathway. In addition, the suppression ofNF-κBa c t i v a t i o nb y
antimony resistant L. donovani results in inhibition of SAG-
induced γGCS heavy-chain (γGCShc) gene expression in
DCs. Regulation of host γ GCShc expression and, therefore,
ofhost GSHlevelbyantimonyresistant L.donovaniisimpor-
tant in the view of antimony resistance in LD infection. This
studyestablishesakeyroleforNF-κBinantimonyresistantL.
donovani -mediated suppression of DCs. Notably, antimony
resistant but not antimony sensitive L. donovani induces
increased IL-10 secretion by DCs. IL-10, a potent suppressor
of antileishmanial immunity, is known to minimize respon-
siveness to SAG. Therefore, increased IL-10 production may
play a criticalrole in disease pathogenesis in thehost infected
with antimony resistant L. donovani. Studies are underway
to conﬁrm whether the inhibition of SAG-induced signaling
pathwaysobservedinantimonyresistant L.donovaniinfected
DCs is due to lack of accumulation of the drug itself (as
observed previously in case of macrophage system) or due
to the eﬀect of antimony resistant L. donovani infection.
3.7. Antimonials for Cancer. The immune system performs
meticulously balanced and harmonious functions and thus
protects the host from any undesirable foreign insult.
Despite the existence of a multifunctional immunosurveil-
lance process, immunocompetent individuals develop can-
cer. Cancer induces immense local immunosuppression and
globalimmunosuppression inlatestage.Antimonialspossess
immunomodulatory activity, can activate multiple signaling
pathwaysincludingNFκB[78],and are also ableto modulate
intracellular redox balace [39]. Antimonial has been shown
to activate T cells, and ameliorate renal cell carcinoma in
combination with IL-2 [172] .S A Ga sw e l la sa n t i m o n yt r i -
oxide have also been shown to possess antileukemic activity
[85, 173–175]. Since antimony is cheap and shows both
direct action as well as indirect action on both immune cells
and tumor cells, therefore antimony compounds are being
tried clinically for cancer therapy mainly against leukemia.
At present novel cost-eﬀective delivery systems for anti-
monials using liposome and cyclodextrin are being devel-
oped by Frezard’s group and are showing enhanced eﬃcacy.
Interestingly cyclodextrin-based [176]antimony delivery has
been found to be orally active. These formulations will not
only improve therapeutic use of antimony for leishmaniasis
but also for other diseases.
3.8. Other Available Drugs
3.8.1. Amphotericin B. Conventional by, amphotericin B
has been used as a second-line treatment for VL since
the 1960s. This drug exhibits an excellent antileishmanial
activity with >90%–95% cure rates in Indian VL cases.
The routine scheme of conventional amhotericin B is
1mg/kg administered on alternate days for a total of 30
days. However, a recent study in India showed 96% cure
rates with a dose of 0.75mg/kg/day for 15 days [176].
Major disadvantages of conventional amphotericin B are its
prolonged administration and the frequent adverse eﬀects,
such as infusion-related fever and chills, nephrotoxicity, and
hypokalemia, which necessitate administration in hospital
[176]. Conventional amphotericin B is used extensively in
India for cases unresponsive to antimonials or even as a ﬁrst
linedrug.However,outsideIndiathisdrugdoesnotoﬀerany
advantage over pentavalent antimonials.
Unresponsiveness and relapses occur rarely, except
among HIV-infected patients. In this population, secondary
episodes of VL are common and are attributed mainly to
relapse but also to reinfection [177]. A recent study failed to
disclose decreased susceptibility among Leishmania parasites12 Molecular Biology International
collected from HIV-infected patients during repeated VL
episodes (mean follow-up period: 35.6 months; range: 3–
137 months), despite repeated courses of amphotericin
B.
3.8.2. Miltefosine. Miltefosine (hexadecylphosphocholine) is
the ﬁrst orally administered drug for VL and the latest to
enter the market. This agent is associated with high eﬃcacy
rates,includingcasesunresponsivetoantimonials[178,179].
In a phase IV multicenter trial in India of 1132 adults and
children with VL treated with miltefosine, cure rates were
82% per intention-to-treat analysis and 95% per protocol
analysis [180]. In this study, 3% of patients developed
adverseeﬀects,mainlygastrointenstinal toxicity,andelevated
hepatic transaminases and creatinine [180]. Datafrom phase
IV clinical trials in India involving domiciliary treatment
with miltefosine along with weekly supervision suggested a
doubling in the relapse rate against miltefosine [180]. So far,
miltefosine is licenced in India, Germany, and Colombia.
The scheme of miltefosine treatment is 100mg/kg/day
for 28 days in adults weighing ≥50kg, 50mg/kg/day in
adults <50kg, and 2.5mg/kg/day in children (maximum
dose: 100mg/day). Major concerns for the wide use of
miltefosine include its teratogenic potential and its long
half-life (approximately 150 hours) which may facilitate the
emergence of resistance. Miltefosine is strictly forbidden in
womenofchild-bearing agewhomaybecomepregnantupto
two months following drug discontinuation. In India milte-
fosineisavailableoverthecounter,afactthatmayexposethis
drug to misuse and emergenceof resistance. Once generated,
resistant parasites could spread rapidly, endangering the life
span of miltefosine in a country where it is needed most [7].
The exact antileishmanial mechanism of miltefosine
remains largely unknown. The intracellular accumulation of
the drug appears to be the critical step for its action. The
intracellular accumulation of miltefosine includes the fol-
lowing steps: binding to plasma membrane, internalization
in the parasite cell (two proteins, the miltefosine transporter
LdMT and its beta subunit LdRos3, are the most signiﬁcant),
and intracellular targeting and metabolism [181]. Ithas been
found that miltefosine induces an apoptosis-like cell death
in L. donovani by producing numerous defects [181]. Milte-
fosine also induces several immunologic and inﬂammatory
eﬀects on macrophages. In animal models, miltefosine does
not require T-cell-dependent immune mechanisms in order
to act, indicating that this agent can be used in T-cell-
deﬁcient patients [182] .R e c e n t l y ,i tw a sf o u n dt h a tm i l t e f o s -
ineenhanced IFN-γ receptorsand thusIFN-γ responsiveness
in L. donovani-infected macrophages; in the same model,
miltefosine induced an IL-12-dependent Th1 response and
reversed the Th2 response to Th1 response [183].
Resistance to miltefosine may emerge easily during
treatment due to single point mutations. Decrease in drug
accumulation is the common denominator in all miltefosine
resistant Leishmania lines studied to date, and this could be
achieved through decreased uptake, increased eﬄux, faster
metabolism, or altered plasma membrane permeability; the
ﬁrst two mechanisms have been already described in models
of experimental miltefosine resistance [184]. Two proteins,
miltefosine transporter LdMT and its speciﬁc beta subunit
LdRos3, form part of the miltefosine translocation machin-
ery at the parasite plasma membrane, and are required
for miltefosine uptake [181]. Experimental mutations at
LdMT or LdRos3 rendered the parasites remarkably less
sensitive to miltefosine, and this resistance persisted in vivo;
cross-resistance with other antileishmanials was not detected
[185]. The overexpression of ABC transporters is another
mechanism for acquisition of miltefosine resistance, through
reduction of the drug intracellular accumulation [185].
Recently,anovelﬂavonoidderivativewas designedanditwas
shown that the use of suboptimal doses in orderto overcome
the overexpression ofLtrMDR1 (a P-glucoprotein-liketrans-
porter belonging to the ATP-binding cassette superfamily)
was associated with a fourfold increase of intracellular
miltefosine accumulation in the resistant Leishmania lines
[186]. Furthermore, modiﬁcations in lipid compositions of
membranes and sterol biosynthesis have been detected in
miltefosine-resistant L. donovani promastigotes [187]. Since
membrane ﬂuidity and permeability are inﬂuenced by lipid
composition, their modiﬁcation may aﬀect drug-membrane
interactions [187]. A case of a healthy patient with VL,
who relapsed 10 months after successful treatment with
miltefosine for 28 days, was reported recently [188].
3.8.3. Paromomycin. Paromomycin (aminosidine) is an
aminoglycoside with antileishmanial activity. In a phase III
study of VL in India, this drug was associated with 94.6%
cure rates, similar to amphotericin B [189]. Adverse eﬀects
were more frequentin theparomomycin-treated groupcom-
paredwiththeamphotericinB-treatedgroup(6%versus2%,
resp.); includedincreased hepatic transaminases, ototoxicity,
and pain at injection-site [189]. Currently, paromomycin is
under phase IV clinical trials. Paromomycin is inexpensive
but requires daily intramuscular injections for 21 days [176].
Paromomycin inhibits protein synthesis and modiﬁes
membrane ﬂuidity and permeability. An in vitro study
showed that following a 72-hour exposure of L. dono-
vani promastigotes and amastigotes to paromomycin, the
mitochondrial potential was decreased, which indicates that
mitochondria arethetargetsofthedrug[190].Inlaboratory-
derived resistant parasites developed through serial-passage
increasing-drug concentrations, paramomycin uptake was
decreased compared to the wild-type parasite, in association
with inhibition of protein synthesis; no cross-resistance with
other antimonial agents was detected [190]. Since paro-
momycin is an aminoglycoside, it is possible that resistance
will emerge rapidly if used as monotherapy.
3.8.4. Combination Regimens. The rational for using com-
bination regimens with diﬀerent resistance mechanisms
over monotherapy relies on the expected enhanced eﬃcacy
(through synergy or additive activity without drug inter-
action), shorter treatment duration, less toxicity, improved
compliance, reduced likelihood of emergence of resistance,
and reduced costs. A combination policy for VL is supported
by the fact that antileishmanial drugs belong to diﬀerent
chemical classes [195]. Recent studies have investigated thisMolecular Biology International 13
option. In a retrospective study conducted among Sudanese
patients with VL, it was found that combination of sodium
stibogluconate and paromomycin administered for 17 days
was associated with higher cure and survival rates compared
to sodium stibogluconate monotherapy administered for 30
days (44%–86% lower odds of death in the combination
group) [191]. Combinations of miltefosine with ampho-
tericin B, paromomycin or pentavalent antimonials have
been evaluated in an in vivo model and this revealed that
the combinations of miltefosine with amphotericin B or
paromomycin were eﬃcacious [192]. These preliminary
data justiﬁed a recent study in Bihar, India, comparing
5mg/kg of liposomal amphotericin B administered once
(group A; 45 patients), 5mg/kg of liposomal amphotericin
B administered once plus miltefosine for either 10 days
(group B; 46 patients) or 14 days (group C; 45 patients),
3.75mg/kg of liposomal amphotericin B administered once
plus miltefosine for 14 days (group D; 45 patients), and
5mg/kg of liposomal amphotericin B administered once
followed by miltefosine for 7 days (group E; 45 patients); in
this study, similar ﬁnal cure rates (91%–98%) were noted
in all treatment groups. These data indicate that a single
dose of liposomal amphotericin B followed by 7–14 days of
miltefosine is active against Indian VL [193]. In this study,
all patients were treated in an outpatient setting. Large,
randomized-controlled trials are required before adaptation
of combination regimens.
Several combination regimens with investigational
agents have been tested in vitro and in animal models [194].
The plant-derived immunostimulant agent picroliv has no
antileishmanial activity; however, when administered with
half-dose miltefosine, it increases signiﬁcantly the activity of
the latter [195].
3.9. Peroxovanadium Compounds towards the Reversal of
Antimony Resistance. There are reports that peroxo- and
diperoxo-vanadate compounds are potential antileishmanial
agents in a number of in vitro and in vivo assays [196, 197].
The peroxide of vanadium (PV, a mixture of vanadate and
H2O2) is an insulinomimetic agent and a potent inhibitor
of protein tyrosine phosphatase (PTP) [198–202]. Inhibition
of PTP by peroxovanadate can modulate the leishmanicidal
response by inducing microbicidal eﬀector molecules (like
NO, ROS) along with IFN-γ [196, 197]. The peroxovanadate
compounds that are used against experimental infection
contain 1,10-phenanthroline, pyridine-2-carboxyl or bipyri-
dine as ancillary ligands [197, 198, 202]. A number of
chemically deﬁned PV derivatives, each containing an oxo
ligand, one or two peroxo anions in the inner coordination
sphere of vanadium, and an ancillary ligand, are equally
potent PTP inhibitors stable in aqueous solution [202].
These can activate the insulin receptor kinase, mimic insulin
biological action in vivo [198], and also activate the response
of immune cells [203]. Bothin human and mice, the severity
of visceral leishmaniasis have been most closely associated
with increased levels IL-10, where the ratio of IFN-γ:IL-
10 is the important denominator for the protection [204–
206]. Thus peroxovanadate complexes appear to possess the
potential to become antileishmanial agents.
We tested a number of vanadium compounds, which
are diﬀerent from those used against experimental infection,
with respect to their ancillary ligands in the coordination
sphere ofthe compounds(Figure 4), toget the potent variety
that may be of therapeutic application against leishmaniasis.
Another compelling reason to test vanadium compounds is
that vanadate is an inhibitor of P-gp [207–209], which is
well related to Sb-resistace in leishmaniasis [210]. We have
studied six peroxovanadate compounds ((three dinuclear
triperoxovanadate (TPV, (a)–(C) in Figure 4)c o m p l e x e s
and three mononuclear diperoxovanadate (DPV, (d)–(f) in
Figure 4) complexes). Our study showed that one of the
mononuclear diperoxovanadate compounds (designated as
PV6) is highly eﬀective in killing intracellular Leishmania
parasites. When PV6 was injected together with SAG, the
combination showed enhanced antileishmanial activity in
vivo in terms of reduction in organ parasite burden in
BALB/cmiceinfected eitherwithSAGsensitive orSAGunre-
sponsive strain. Our study also showed that immune param-
eters likeantileishmanial T cell response as also ROS and NO
production were enhanced in response to the combination
treatment. Mostimportantly, suchtherapy allowed increased
IFN-γ productionwith concomitantdecrease inIL-10gener-
ation, an indicator for favorable antileishmanial immune.
4.StrategiesAvailableto
CombatDrugResistance
4.1.DrugResistance Monitoring. Improvedmethodstomon-
itor drug resistance are essential that determine either the (i)
phenotypic sensitivity of parasite isolates or (ii) molecular
changes that indicate alterations in either the drug target
or mechanisms that alter the intraparasite level of active
drug. There are problems with both approaches. First, the
determinationofdrugsensitivityofclinicalisolatesisopento
the criticism that pathogen adaptation from host to culture
media immediately selects for a subpopulation of pathogens
best suited for growth in that medium. The drug sensitivity
of parasites must therefore be tested as soon as possible after
isolation from the patient using deﬁned agreed protocols.
Although promastigote assays are easiest and quickest, this
assay is not predictive for pentavalent antimonials, and pos-
sibly not for other antileishmanials also, for example, paro-
momycin, pentamidine, and miltefosine. The amastigote-
macrophage assay is currently the only model able to
correlate clinical response to the sensitivity of the isolate,
as demonstrated in relation to pentavalent antimonials [3].
Axenic amastigotes are sensitive to antimonials but adapta-
tion of isolates is both too selective and too lengthy a process
to be used in this type of assay [211]. Second, the ability
to develop molecular probes or PCR-based diagnostics to
monitor the development and spread of drug resistance is
severely limited by a lack of knowledge of the molecular and
biochemical mechanisms of action and resistance of most
antileishmanial drugs, especially in clinical isolates [114].
4.2. Monitoring Therapy. The introduction of an oral drug
for leishmaniasis oﬀers advantages of improved compliance,
self administration, and reduced costs. In the phase IV trial14 Molecular Biology International
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Figure 4: Structures and formulae of the PV compounds [218].
for miltefosine, a 7-day supply is issued to patients who have
to return to the clinic each week for examination and re-
supply. For drugs like miltefosine which have a long half-
life and a propensity for selection of resistant forms, the
monitoring of daily dosing and the completion of a course
of treatment are essential. The directly observed treat-
ment strategy for tuberculosis chemotherapy has been suc-
cessfully introduced in India by the Revised National
TB Control Programme in 1997 (http://www.who.int/gtb/
publications/globerep/index.html). The potential for use
of a parallel system for the control of leishmaniasis, for
miltefosine at presentpossibly also forsitamaquine in future,
should be considered [114].
4.3. Cost and Distribution of Drugs. The approximate cost
of treatment of a patient with VL in India is given in
Progressive failure of antimonial drug treatment, which
is the only available drug treatment in the public health
program in India, has driven most of the VL patients
in India towards the private sector. The drugs, including
antimonials, amphotericin B, and now miltefosine, can be
bought over the counter without restriction on quantity.
The cash-starved population buys antileishmanial drugs in
instalments, and most do not complete treatment [102]a s
diseasesymptoms arealleviatedquickly.Consideringthecost
ofdrugs,antimonialshavebeentheonlydrugsthatarebarely
aﬀordable. Miltefosine, which is being used extensively inMolecular Biology International 15
the private sector, is ∼6 times more expensive and it is not
mandatory to buy the full course. This is likely to result in
widespread underdosing, sharing of doses among patients,
and ultimately emergence of resistance to this important
and only oral antileishmanial compound. Considering the
inability of the majority of the population to purchase and
complete a full course of the drug, and the chaotic system
of drug marketing, it has been suggested that, miltefosine
should be withdrawn from the private sector and made
available free through public and/or private health care
providers to prolong the eﬀective life of this important drug
[7].
4.4. Diagnostic Methods. The improvement in noninvasive
serological diagnostic methods with high sensitivity and
speciﬁcity, for example, DAT, K39, and Katex (urine dip-
stick), is a major advance in the control of leishmaniasis
[212, 213]. In the context of chemotherapy what is required
is a noninvasive diagnostic kit that can be used to monitor
drug response and determine cure in patients. Antibody
levels do not always indicate active infection, vary between
individuals, and are of no use in HIV/VL coinfection cases.
Antigen detection is far more important for monitoring
drug response; further improvement of methods such as
the Katex kit [214] might be of particular interest in
this case. The variation in species sensitivity has greatest
clinicalsigniﬁcance in Centraland SouthAmerica, where the
distribution of L. mexicana, L. amazonensis, L. panamensis,
L. braziliensis, and other members of these groups overlap.
The distinctive amastigote and macrophage interaction of
mexicana group parasites makes some level of diagnosis by
microscopy feasible for trained staﬀ. Molecular tools that
have been developed need to be implemented to distinguish
the braziliensis group species.
4.5. Combination Therapies. Drug combinations have
proven to be essential features of antimicrobial treatment
through design or use to (i) increase activity through use of
compounds with synergistic or additive activity, (ii) prevent
the emergence of drug resistance, (iii) lower required
doses, reducing chances of toxic side eﬀects and cost, or
(iv) increase the spectrum of activity, for example, the use
of an antileishmanial with either an antiinﬂammatory or
immunodulatorin cutaneousleishmaniasis. Previousstudies
on drug combinations for VL, for example allopurinol plus
sodium stibogluconate and paromomycin plus sodium
stibogluconate [215]. The use of combinations to combat
resistance has been well rehearsed in antimalarials; studies
to identify such combinations are new for leishmaniasis;
limited studies are under way to examine interactions of
miltefosine with other antileishmanials to identify suitable
combinations. Bryceson [216] advocated the examination
of combinations of strong antileishmanials with “weak”
drugs (e.g., azoles); this is an approach also used in malaria
treatment, for example, the inclusion of clindamycin or
azithromycin in combinations. A combination therapy also
needstobeevaluatedforsafety andoptimized foreithercon-
comitant or sequential administration of component drugs.
4.6. Resistance Reversal Agents. The strategy to reverse resis-
tance has long been discussed in relation to chloroquine
resistance in Plasmodium falciparum and produced inter-
esting experimental results without any clinical impact. In
laboratory studies on Leishmania, a series of sesquiterpenes
have been shown to reverse drug resistance due to P-
glycoproteinsin an L. tropica clone. Another study suggested
a strategy of inhibition of thiol levels by coadministration of
antimony with an inhibitor of glutathione biosynthesis.
4.7. New Targets, New Drugs. There are few better ways to
avoid drug resistance than to have an adequate armory
of drugs with diﬀerent targets and no cross-resistance.
Although miltefosine has been approved for use in the treat-
ment of VL in India, paromomycin is moving through phase
III trials in India and Africa, and sitamaquine remains in
phase II development for leishmaniasis [217], all these drugs
have clear limitations of toxicity, long courses of treatment,
or parenteral administration. More clearly deﬁned criteria
of the needs and target proﬁles for new drugs and new
treatments are required.
5.Conclusions
The control of VL globally is challenged by the widespread
emergence of antimonial resistance in India. In the last
decade new formulations of conventional antileishmanial
drugs as well as new agents became available. The wide use
of the oral agent miltefosine was hampered by the potential
for teratogenicity and emergence of resistance. Combination
regimens should be evaluated in large trials. During last
few years several mechanisms of in-ﬁeld antileishmanial
resistance were identiﬁed. Understanding their molecular
and biochemical characteristics will lead to the design of new
drugs and also the molecular surveillance of resistance. In
order not to jeopardize the life span of available antileishma-
nials, their delivery, clinical response, and resistance should
be monitored. Overall the development of antileishmanials
has been generally slow; new drugs are needed.
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